Comparable stake leader
VIKING GLOBAL INVESTORS LP
SEC ownership of Adaptive Biotechnologies Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001478320.
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
7/50
Latest evidence
17 Aug 2026
- Public ticker
- ADPT on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
VIKING GLOBAL INVESTORS LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
7 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
VIKING GLOBAL INVESTORS LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001478320
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Adaptive Biotechnologies Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
7/50
Latest evidence
17 Aug 2026
13F
13D/G
3/4/5
Lead comparable stake: 19%
43 rows are not safely comparable across share classes.
13D/G row: VIKING GLOBAL INVESTORS LP
Showing 1-8 of 50 holder rows.
Quick read
VIKING GLOBAL INVESTORS LP leads the comparable SEC ownership view at 19%.
7 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Comparable ownership
Top 5
VIKING GLOBAL INVESTORS LP
19%
BlackRock, Inc.
7.9%
Amova Asset Management Americas, ...
4.6%
Sumitomo Mitsui Trust Group, Inc.
4.6%
INTEGRATED CORE STRATEGIES (US) LLC
4.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13F
13D/G
Company
|
19%
Reported 13D/G
· 31 Mar 2026
|
$643,365,037
29,993,708 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.9%
Reported 13D/G
· 31 Dec 2025
|
$324,734,962
15,139,159 shares
|
— | 30 Jun 2026 |
| Amova Asset Management Americas, Inc. |
13D/G
13F
Nikko Asset Management Americas, Inc. · Company
|
4.6%
Reported 13D/G
· 31 Dec 2024
|
$53,981,782
6,833,137 shares
|
$0 | 31 Dec 2024 |
| Sumitomo Mitsui Trust Group, Inc. |
13D/G
13F
Company
|
4.6%
Reported 13D/G
· 31 Dec 2024
|
$53,981,782
6,833,137 shares
|
$0 | 31 Dec 2024 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
4.3%
Reported 13D/G
· 31 Dec 2024
|
$49,711,809
6,292,634 shares
|
$0 | 31 Dec 2024 |
| Rubric Capital Management LP |
13D/G
|
4.1%
Reported 13D/G
· 30 Jun 2025
|
$72,889,139
6,256,847 shares
|
$0 | 30 Jun 2025 |
| ARK Investment Management LLC |
13F
13D/G
Company
|
2.9%
Reported 13D/G
· 31 May 2025
|
$44,837,058
2,090,306 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$137,356,941
6,403,587 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$130,370,038.
Buys
$0
Insiders: 0
Sells
$130,370,038
Insiders: 11
Net
-$130,370,038
Shares: -7,137,791
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 7,137,791
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 1,202,950 | $0 | $30,795,812 | -$30,795,812 |
| 3-6 | 0 | 1,474,932 | $0 | $31,518,990 | -$31,518,990 |
| 6-9 | 0 | 2,847,448 | $0 | $40,300,823 | -$40,300,823 |
| 9-12 | 0 | 1,612,461 | $0 | $27,754,413 | -$27,754,413 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to Adaptive Biotechnologies Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Chad M. Robins
Net 12M change
-$130.37M
Full value: -$130,370,037 · USD · 12-month changeLatest report
30 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | $54,818,222 | -$39,801,326 | -42% | Filing P/S | 17 Aug 2026 |
| Harlan S. Robins | Chief Scientific Officer | $17,962,722 | -$29,647,952 | -62% | Filing P/S | 21 Jul 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | $11,680,500 | -$1,397,396 | -11% | Filing P/S | 06 Oct 2026 |
| Julie Rubinstein | President and COO | $9,815,295 | -$20,854,423 | -68% | Filing P/S | 30 Oct 2026 |
| Francis Lo | Chief People Officer | $6,372,629 | -$13,894,486 | -69% | Mixed | 01 Oct 2026 |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | $4,677,816 | -$14,690,979 | -76% | Filing P/S | 26 Jun 2026 |
| Kyle Piskel | Chief Financial Officer | $3,347,694 | -$3,581,680 | -52% | Filing P/S | 18 May 2026 |
| Peter M. Neupert | Director | $3,286,525 | -$3,135,850 | -49% | Filing P/S | 17 Aug 2026 |
| Tycho Peterson | Chief Financial Officer | $1,828,542 | Filing P/S | 04 Mar 2024 | ||
| Katey Einterz Owen | Director | $1,417,845 | -$249,990 | -15% | Mixed | 31 Aug 2026 |
| Ph.D. Robert Hershberg MD | Director | $1,139,532 | -$1,115,696 | -49% | Filing P/S | 18 Aug 2026 |
| Nitin Sood | Chief Commercial Officer, MRD | $887,157 | Mixed | 07 Aug 2023 | ||
| R. Mark Adams | Chief Operating Officer | $724,241 | Mixed | 10 Apr 2023 | ||
| Stacy L. Taylor | SVP and General Counsel | $626,780 | Filing P/S | 22 Aug 2024 | ||
| Michael J. Pellini | Director | $553,339 | Mixed | 04 Mar 2025 | ||
| Michelle Renee Griffin | Director | $315,312 | -$2,000,259 | -86% | Filing P/S | 25 Jun 2026 |
| Henning Thorsen | SVP, Commercial Operations | $120,022 | Mixed | 17 May 2021 | ||
| Leslie Trigg | Director | $106,996 | Mixed | 06 Mar 2023 | ||
| Conroy Kevin T. | Director | $94,858 | Mixed | 06 Mar 2023 | ||
| Chad M. Cohen | Chief Financial Officer | $89,225 | Mixed | 22 Dec 2021 |
Recent insider transactions for Adaptive Biotechnologies Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$308,668 | $25.98 | -11,881 | 377,802 | 03 Nov 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 03 Nov 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -11.2% | -11,881 | 94,633 | 03 Nov 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$302,627 | $25.47 | -11,881 | 377,802 | 02 Nov 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 02 Nov 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -10% | -11,881 | 106,514 | 02 Nov 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$317,596 | $26.73 | -11,881 | 377,802 | 30 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 30 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -9.12% | -11,881 | 118,395 | 30 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$335,876 | $28.27 | -11,881 | 377,802 | 29 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 29 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -8.36% | -11,881 | 130,276 | 29 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$337,988 | $28.45 | -11,881 | 377,802 | 28 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 28 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -7.71% | -11,881 | 142,157 | 28 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$324,234 | $27.29 | -11,881 | 377,802 | 27 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 27 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -7.16% | -11,881 | 154,038 | 27 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$309,409 | $26.04 | -11,881 | 377,802 | 26 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 26 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -6.68% | -11,881 | 165,919 | 26 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$296,842 | $24.98 | -11,881 | 377,802 | 23 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 23 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -6.26% | -11,881 | 177,800 | 23 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$291,206 | $24.51 | -11,881 | 377,802 | 22 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 22 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -5.89% | -11,881 | 189,681 | 22 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$301,877 | $25.41 | -11,881 | 377,802 | 21 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 21 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -5.57% | -11,881 | 201,562 | 21 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$291,473 | $24.53 | -11,881 | 377,802 | 20 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 20 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -5.27% | -11,881 | 213,443 | 20 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$285,738 | $24.05 | -11,881 | 377,802 | 19 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 19 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -5.01% | -11,881 | 225,324 | 19 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$288,011 | $24.24 | -11,881 | 377,802 | 16 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 16 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -4.77% | -11,881 | 237,205 | 16 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$304,272 | $25.61 | -11,881 | 377,802 | 15 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 15 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -4.55% | -11,881 | 249,086 | 15 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$305,072 | $25.68 | -11,881 | 377,802 | 14 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 14 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -4.35% | -11,881 | 260,967 | 14 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$302,966 | $25.50 | -11,881 | 377,802 | 13 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 13 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -4.17% | -11,881 | 272,848 | 13 Oct 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -3.05% | -$303,127 | $25.51 | -11,881 | 377,802 | 12 Oct 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.14% | 11,881 | 389,683 | 12 Oct 2026 | Direct |
* marks a reported price that did not pass the local price check.